Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532542 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
A Phase 3 study, sponsored by Sarepta Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 171
- Enrollment target
NCT03532542: Clinical Trial Phase 3 study, sponsored by Sarepta Therapeutics.
NCT03532542 is a Phase 3 study that was terminated before completion, run by Sarepta Therapeutics. The registered enrollment target is 171 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03532542, a Phase 3 study, was terminated before completion, sponsored by Sarepta Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 171 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Primary Outcome
A treatment-emergent adverse event (TEAE) was any untoward medical occurrence in a clinical study participant that did not necessarily have a causal relationship with the study drug. A TEAE could, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurred during or after administration of the study drug, whether or not considered related to the study drug. A TESAE was any TEAE that resulted in any of the following outcomes: death, a life-thr
Interventions
- DRUG Casimersen
- DRUG Golodirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2023-07-26 |
| Phase | Phase 3 |
Why NCT03532542 stopped before completion
NCT03532542 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Casimersen is the first listed.
NCT03532542 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03532542 about?
NCT03532542 is a clinical study titled "An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy". The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
What is the current status of trial NCT03532542?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 171 participants. The study started on 2018-08-02. Estimated completion is 2023-07-26.
What interventions are being tested in trial NCT03532542?
The interventions under investigation include: Casimersen (DRUG), Golodirsen (DRUG).
Who is sponsoring clinical trial NCT03532542?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03532542's enrollment target sits among peer trials
171 1451st of 2000 higher than 548 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI